Celldex price target raised to $15 from $9 at Jefferies Jefferies increased its price target on Celldex as the firm believes that the company's pipeline outlook was encouraging. The firm views Celldex as a compelling biotech play with multiple shots on goal and it maintains a Buy rating.
Celldex appoints Richard Wright as Chief Commercial Officer Celldex Therapeutics announced the promotion of Richard Wright, Ph.D. to SVP and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex's cancer immunotherapy pipeline.